News|Videos|March 18, 2026

What is the Next Threat Manufacturers at Access USA Need to Be Preparing For?

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing manufacturers toward more sophisticated, partnership-driven program designs.

Matthew Turner, President of Patient Affordability, Paysign

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical manufacturers, such as accumulators, maximizers, and alternative funding programs. In a conversation with Pharmaceutical Executive, Turner emphasized the importance of next-generation copay assistance programs, which involve strategic partnerships across various ecosystem components.

A transcript of Turner’s conversation with Pharmaceutical Executive can be found below.

Pharmaceutical Executive: As you look out across the landscape at Access USA, what is the next threat manufacturers need to be preparing for?

Matthew Turner: So I think the threats evolve as these outside payer organizations evolve their attacks on the manufacturer co-pay program. So initially it was accumulators, then it morphed into maximizers, then it morphed into alternative funding programs.

We started seeing people push more things into PAP, and I think that is the type of evolution we're going to see within those tools. I think we're going to see the programs shift and change to where people try to make them less obvious to providers like ourselves, so it's more difficult for us to find.

Pharmaceutical Executive: What conversations are standing out to you at the conference?

Matthew Turner: I think part of what I'm seeing, if you walk through the trade show hall, is there's a lot of small companies there. It's not dominated by three or four large companies. There's a lot of people that are doing boutique services that are trying to focus on very specific disease states.

The discussion around those partnerships across everybody here is what I think is leading me to believe that people are looking more at program design, and not just in the copay space, but in every service that they're bringing to the table, and I think the partnership aspect is really a driving factor in these types of events.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.